Explore the Agenda
7:00 am Check In, Morning Coffee & Light Refreshments
7:55 am Chair’s Opening Remarks
Spotlighting ADC Clinical & Approval Success Across 2024 & 2025 Driving ADC Access to Wider Patient Populations
8:00 am Showcasing Pivotal-Stage Clinical Performance of Sigvotatug Vedotin & PDLIV ADCs in Combination with Keytruda For First-Line Thoracic Cancers
- Exploring late-stage clinical data of Sigvotatug vedotin and PDLIV ADCs in combination with Keytruda, highlighting the significance of vedotin ADCs causing immunogenic cell death vs. Topo1 ADCs
- Delving into rationale and synergistic benefit of Keytruda combination approach in thoracic cancers
- Laying out potential for Sigvotatug vedotin and PDLIV combinations to improve thoracic cancer standard of care and impact oncology patientsÂ
8:30 am ADC Manufacturing Strategy & Solutions
- Discussing tools used for the efficient and scalable manufacturing of the mAb intermediate, which serves as a key starting point for ADC conjugation
- Highlighting various chromatography systems and resins used in the process, such as the ÄKTA™ systems and MabSelect PrismA™ resin, which are designed for robustness and efficient purification
- Presenting the compatibility of materials in single-use systems with solvents used in the ADC manufacturing process, detailing the steps involved in the analysis
9:00 am Exploring the Clinical Profile & Journey of Datroway from TROPION-Breast Trials & Assessing Future Directions in Solid Tumor Indications
- Detailing clinical data from TROPION-Breast01 trial with US and Japanese approval in previously metastatic HR positive, HER2 negative breast cancer
- Exploring fresh insights from TROPION-Breast02 in triple negative breast cancer
- Looking ahead to TROPION-Breast 03, 04, and 05 trials and highlighting other investigations of Datroway in solid tumorsÂ
9:30 am From IND to Long Term Commercial Supply: a Step Ahead Against the Challenges of the Bioconjugates
- Serving the innovators from the candidate selection to the IND, from Phase I to the long term commercial supply
- Highlights on the approach to support early stage program through robust development studies
- Overview on conjugation and fill/finish capabilities
- Delivering important updates on conjugation and fill-finish capacity
Discovery Chemistry
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
Discovery Chemistry
Contrasting Design & Efficacy of Dual Payload ADCs Versus Classical Mono-Payload Design
4 Sessions
Presentation Sneak Peek:
Chief Scientific Officer, ADC Therapeutics
Exploring a Rational Design Approach to Novel Exatecan-Based Payloads for Application in Dual Conjugate ADCs
- Exploring the prospect of dual conjugate ADCs versus classic ADC design
- Assessing generation of novel exatecan based linker-drugs to maximize the design space for dual conjugate ADCs
- Examining selection of targets and payload combinations for dual conjugate ADCsÂ
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
1:00 pm Lunch & Networking
Discovery Chemistry
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
Discovery Chemistry
Leveraging Linker Chemistry to Widen Payload Applications & Therapeutic Index
3 Sessions
Presentation Sneak Peek:
Chief Scientific Officer, ADC Therapeutics
Exploring a Rational Design Approach to Novel Exatecan-Based Payloads for Application in Dual Conjugate ADCs
- Exploring the prospect of dual conjugate ADCs versus classic ADC design
- Assessing generation of novel exatecan based linker-drugs to maximize the design space for dual conjugate ADCs
- Examining selection of targets and payload combinations for dual conjugate ADCsÂ
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
3:30 pm Afternoon Break & Networking
Putting the Why Behind ADC Clinical Profiles & Learning From the Past to Lay the Groundwork For Next Generation ADCs
4:00 pm From Cell Painting to AI Assisted CT Scans: Holistically Using Science & Medicine to Better Monitor, Prevent & Detect Interstitial Lung Disease in Solid Tumor Patients Treated with ADCs
- Evaluating distinctive trends in ADC clinical trials and real-world data to characterize areas for risk mitigation
- Establishing a non-clinical toolbox for comprehending pathophysiologic mechanism of action to support ADC asset design and screening
- Embracing innovative, non-traditional methods to elevate risk comprehension to better select patients or decrease incidence of ILD
4:30 pm A Versatile Approach to Generating Next-Generation Antibody Conjugates Through AJICAP® Technologies
- AJICAP Conjugation: Leveraging site-specific Technologies in next-generation ADCs to enhance clinically relevant biological properties through precise DAR control such as 1, 2, 4, 8 and higherÂ
- AJICAP® Linker: Demonstrating a novel hydrophilic linker technology that enhances stability and enables versatile synthesis of ADCs with higher DAR numbers, even with highly hydrophilic payloads
- Application for new modality conjugates: Bispecific antibodies and AOCs produced by fully chemical conjugation technology
5:00 pm From Bench to Breakthrough: The Evolution of Amanitin ADCs – Insights from HDP-101 Phase I/II & the Future of Payload Differentiation
- Differentiation through payloads: showcasing amanitin payloads and stressing the need for new ADC payload MoAs
- Exploring Phase I/II dose expansion data of HDP-101 and evaluating clinical performance against conjugates with validated payloadsÂ
- Reflecting on the development journey of HDP-101 to understand the hurdles to overcome with bringing a novel ADC payload to the clinic
5:30 pm Contextualizing Historical Successes & Challenges in ADCs to Set Up Future ADC Development for Success
- Deep diving into the comprehensive and chequered history of ADCs to understand how they have progressed towards standard of care oncology treatmentsÂ
- Translating past ADC successes and failures into 2025 and beyond: how can these lessons be applied to improve ADC design and development?
- Hypothesizing future directions for the ADC field to evaluate predictions for next generation ADCs and understanding the innovation to make it a realityÂ